Almac Clinical Technologies Announces Participation in the Avoca Diligent Prequalification Platform

April 25, 2016

Diligent Leverages Avoca Quality Consortium Standards Improve Quality and Reduce Cycle Time in the Prequalification of Technical Providers.

Souderton, PA., USA, – 25 April 2016 – Almac Clinical Technologies, a member of the Almac Group and the world’s leading provider of Interactive Response Technology (IRT) is pleased to announce its participation in the Avoca Diligent Prequalification Platform. The purpose of this initiative is to increase quality, improve efficiency, reduce risk, and accelerate technical service provider onboarding by centralising aspects of prequalification activities.

Diligent started by engaging an expert Advisory Board from the Avoca Quality Consortium to develop Industry Standards for Prequalification of technical service providers. These standards were mapped, when possible, to health authority regulations or regulatory guidance. They underwent a rigorous review by The Avoca Group, The Advisory Board, and companies in the industry that deliver these technical services. Upon finalising the Prequalification Industry Standards, prequalification tools were developed that map back to these standards, including Request for Information (RFI) templates.

The Avoca Group has been inviting leading technical service providers to complete core and technical RFI templates and centralise them so they are readily available to sponsors (and CROs, if applicable), to speed up the process of prequalifying and onboarding new technical providers. Almac Clinical Technologies is an early adopter for this transformational initiative and invites sponsors and CROs to contact The Avoca Group at [email protected] to request these completed RFIs as needed to accelerate their review and onboarding of Almac Clinical Technologies for their clinical trials.

“The Avoca Group is pleased to have Almac Clinical Technologies as a participant in Diligent,” said Patricia Leuchten, CEO of The Avoca Group. “It demonstrates Almac’s commitment to moving the industry forward in driving quality, standardising and streamlining processes.”

Bill Kane, Director of Quality Assurance for Almac commented: “Almac Clinical Technologies has been an active member of the Avoca Consortium for a number of years now, and a strong supporter of sharing quality principles and establishing uniform industry quality standards. Our involvement with Avoca has been of exceptional business value to Almac and is yet another way for us to demonstrate our commitment of Quality to our many partners in the Clinical Development industry.”

About Almac Clinical Technologies

Almac Clinical Technologies helps the biopharmaceutical industry bring new therapies to those in need by empowering trial sponsors and CROs to proactively manage sites, patients, and clinical supplies through our industry-leading technology and expert consultancy. For over two decades, Almac Clinical Technologies has maintained its reputation for being the most trusted ally for enabling real-time control of the most critical elements in protocol execution.

About Almac Group

‘Partnering to Advance Human Health’

The Almac Group is an established contract development and manufacturing organisation that provides an extensive range of integrated services to over 600 companies globally within the pharmaceutical and biotech sectors. The services range from R&D, biomarker discovery and development, API manufacture, formulation development, clinical trial supply, IXRS® technology (IVRS/IWRS) through to commercial-scale manufacture.

The international company is a privately owned organisation that has organically grown over 40 years and now employs in excess of 4,000 highly skilled personnel. Almac is headquartered in Craigavon, Northern Ireland with operations across the US (Pennsylvania, North Carolina and California) and in Asia (Singapore and Tokyo).

For more information visit or e-mail [email protected].


Back to news